New Study Reveals StriVectin® Gains Holistic Understanding Of The Melanin Formation Journey

NEW YORK, May 11, 2015 /PRNewswire/ -- StriVectin^®, the pioneer in clinical skin care, announces findings from a research initiative helmed by Smitha Rao, the brand's Vice President of Product Development. Results of the study were presented on May 8^th at the Society for Investigative Dermatology 2015 annual meeting in Atlanta, GA, showcasing the efficacy of the brand's formula as compared to the current industry standard for skin lightening.

As part of the brand's commitment to cutting edge research and development for advanced skincare solutions, the StriVectin^® product development team has long been at the forefront of creating scientific answers to various skincare concerns. One such area of interest is skin tone modulation for photo-damaged skin, due to research revealing that uneven skin tone and discoloration is the number one anti-aging concern in Asia, and among the top five concerns of American women between the ages of 18-54.

"It wasn't enough for us to gain understanding of just part of the problem, so we made it our mission to glean an acutely holistic approach – investigating all three stages of discoloration," confirms Rao. "At StriVectin^® we benchmark ourselves against the best-in-class ingredients at the time of formulation and, from there, aim to improve on the category offerings, blazing a trail towards the future of skin care."

The groundbreaking new study tested a series of compounds in various iterations including phytochemical fermentation based extracts, peptides, vitamins and small molecules in combination with patented NIA-114™ technology for skin brightening efficacy against top skin lighteners—namely, hydroquinone—recommended by scientists and dermatologists worldwide. 

Rao's research led them to develop a composition of high performance ingredients that addresses not just one but three of the ways that skin surface discoloration can occur in skin. Due to this unique intricate approach, when tested against hydroquinone it was proven to be more efficacious*.  This enabled the development of the brand's new Brighten & Perfect range, a high-performance formula with a multi-pronged approach targeting the fundamental causes of excessive pigmentation and discoloration.

"Challenging ourselves to arrive at the root of skin issues, and not simply stopping at quick fixes that scrape the cosmetic surface of a problem, Rao's findings have catapulted us above and beyond our expectations," says StriVectin^® CEO, JuE Wong. "We're thrilled with the acknowledgement, and even more so with the fact that we are now armed to usher another well-rounded, proven skin solution to market."

StriVectin^® presented its findings to the scientific community at the Society for Investigative Dermatology annual meeting and the scientific committee accepted the publication as original research.  The poster, titled Evaluation of a topical skin formulation containing myristyl nicotinate for modulating melanin production in comparison to a formulation containing hydroquinone, was unveiled by Rao at the May 8th event.

About StriVectin^®: StriVectin^®, the largest independent prestige skin care company, faces the future of clinical anti-aging with a collection of formulas developed with patented NIA-114™ technology to achieve healthy and ageless looking skin. Backed by science and rigorous clinical validation, StriVectin is at the forefront of skin care technology and product innovation.  Its revolutionary wrinkle-fighting moisturizer SD Advanced™ Intensive Concentrate for Wrinkles & Stretch Marks is a best-seller around the world.  StriVectin products are sold through department stores and specialty retailers in North America, Europe, the Middle East, Australia and Asia. The company maintains corporate offices in New York, NY.  For more information, visit strivectin.com.

*In vitro evaluation on tanned epidermis against hydroquinone

Contact:  Olivia Porcello: (212) 230-1800 / [email protected]; 
Victoria Natenzon: (212) 230-1800 / [email protected]

SOURCE StriVectin